Skip to main content
SpringerLink
Log in

Interferon therapy of hematologic malignancies

  • Chapter
Biological and Hormonal Therapies of Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 94))

Abstract

Chronic myelogenous leukemia (CML) is a hematologic neoplasm characterized by the proliferation and accumulation of mature myeloid cells and their progenitors. It is a clonal disorder caused by somatic mutation in a pluripotent hematopoietic stem cell; consequently, there is involvement of myeloid and erythroid cells, monocytes/macrophages, megakaryocytes, and lymphocytes. Clonality has been conclusively demonstrated by polymorphic genetic systems such as glucose 6-phosphate dehydrogenase (G6PD) in heterozygous individuals with CML, X-chromosome DNA restriction fragment-length polymorphism of hypoxanthine glucuronyl ribosyl phosphoryl transferase, and the presence of the Philadelphia (Ph’) chromosome and other clonal cytogenetic markers [1-5].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. 1977. Chronic myelocytic leukemia. Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/ macrophage. Am J Med 63:125–130.

    PubMed  CAS  Google Scholar 

  2. Champlin RE, Golde DW. 1985. Chronic myelogenous leukemia: recent advances. Blood 65:1039–1047.

    PubMed  CAS  Google Scholar 

  3. Fauser AA, Kanz L, Bross KJ, Löhr GW. 1985. T cells and probably B cells arise from the malignant clone in chronic myelogenous leukemia. J Clin Invest 75:1080–1082.

    PubMed  CAS  Google Scholar 

  4. Nitta M, Kato Y, Strife A, Wachter M, Fried J, Perez A, Jhanwar S, Duigou-Osterndorf R, Chaganti RSK, Clarkson B. 1985. Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia. Blood 66:1053–1061.

    PubMed  CAS  Google Scholar 

  5. Jones D, Ltibbert M, Kawasaki ES, Henke M, Bross KJ, Mertelsmann R, Herrmann F. 1992. Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood 79:1017–1023.

    Google Scholar 

  6. Nowell PC, Hungerford DA. 1960. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497–1501.

    Google Scholar 

  7. Rowley JD. 1973. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293.

    PubMed  CAS  Google Scholar 

  8. Kurzrock R, Gutterman JU, Talpaz M. 1988. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990–998.

    PubMed  CAS  Google Scholar 

  9. Van Etten RA, Jackson P, Baltimore D. 1989. The mouse type IV c-abi gene product is a nuclear protein and activation of transforming ability is associated with cytoplasmic localization. Cell 58:669–678.

    PubMed  Google Scholar 

  10. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. 1990. Acute leukaemia in bcr/abl transgenic mice. Nature 344:251–253.

    PubMed  CAS  Google Scholar 

  11. Daley GQ, Van Etten RA, Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science 247:824–830.

    PubMed  CAS  Google Scholar 

  12. Herrmann F, Komischke B, Kolecki P, Ludwig WD, Sieber G, Teichmann H, RĂ¼hl H. 1984. Ph’ positive blast crisis of chronic myeloid leukaemia exhibiting features characteristic of early T blasts. Scand J Haematol 32:411–416.

    PubMed  CAS  Google Scholar 

  13. Griffin JD, Tantravahi R, Canellos GP, Wisch JS, Reinherz EL, Sherwood G, Beveridge RP, Daley JF, Lane H, Schlossman SF. 1983. T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood 61:640–644.

    PubMed  CAS  Google Scholar 

  14. Clarkson B. 1985. Chronic myelogenous leukemia: Is aggressive treatment indicated? J Clin Oncol 3:135–139.

    PubMed  CAS  Google Scholar 

  15. Fitzgerald D, Rowe JM, Heal J. 1986. Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am J Hematol 22:213–218.

    PubMed  CAS  Google Scholar 

  16. Goldman JM, Grosveld G, Baltimore D, Gale RP. 1990. Chronic myelogenous leukemia - the unfolding saga. Leukemia 4:163–167.

    PubMed  CAS  Google Scholar 

  17. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. 1993. Chronic myelogenous leukemia: a concise update. Blood 82:691–703.

    PubMed  CAS  Google Scholar 

  18. Herzig RH, Phillips GL, Lazarus HM, et al. 1985. High-dose cytarabine for the treatment of blastic phase chronic myelogenous leukemia. Cancer Treat Rep 69:881–883.

    PubMed  CAS  Google Scholar 

  19. Delage R, Ritz J, Anderson KC. 1990. The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am 4:369–388.

    PubMed  CAS  Google Scholar 

  20. Talpaz M, Kantarjian HM, McCredie KB, et al. 1987. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280–1288.

    PubMed  CAS  Google Scholar 

  21. Talpaz M, Kantarjian HM, McCredie K, et al. 1986. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 314:1065–1069.

    PubMed  CAS  Google Scholar 

  22. Alimena G, Morra E, Lazzarino M, et al. 1988. Interferon alpha-2b as therapy for Ph’-positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent or daily administration. Blood 72:642–647.

    PubMed  CAS  Google Scholar 

  23. Niederle N, Kolki O, Osieka KR, et al. 1987. Interferon alpha-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 16:29–35.

    Google Scholar 

  24. Ozer H, George SL, Schiffer CA, et al. 1993. Prolonged subcutaneous administration of recombinant alb interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975–2984.

    PubMed  CAS  Google Scholar 

  25. Freund M, Von Wussow P, Diedrich H, et al. 1989. Recombinant human interferon (IHN) alpha-2b in chronic myelogenous leukemia - dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350–356.

    PubMed  CAS  Google Scholar 

  26. Kluin-Nelemans JC, Louwagie A, Delannoy A, et al. 1992. CML treated by interferon alpha-2b vs hydroxyurea alone - preliminary report of a large multicenter randomized trial (abstract). Blood 80 (Suppl 1):358a.

    Google Scholar 

  27. Tura S, Baccarani M, Zuffa E, et al. 1994. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820–825.

    Google Scholar 

  28. Schofield JR, Robinson WA, Murphy JR, Rovira DK. 1994. Low doses of interferon-a are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121:736–744.

    PubMed  CAS  Google Scholar 

  29. Ronnblom LE, Alm FV, Oberg KE. 1991. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115:178–183.

    PubMed  CAS  Google Scholar 

  30. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. 1990. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65:2237–2242.

    PubMed  CAS  Google Scholar 

  31. Sacchi S, Kantarjian H, O’Brien S, Cohen PR, Pierce S, Talpaz M. 1995. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13:2401–2407.

    PubMed  CAS  Google Scholar 

  32. Allan NC, Richards SM, Shepherd PCA. 1995. UK Medical Research Council randomised, multicentre trial of interferon-ant for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 345:1392–1396.

    PubMed  CAS  Google Scholar 

  33. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, et al. 1994. Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064–4077.

    PubMed  CAS  Google Scholar 

  34. Ohnishi K, Ohno R, Tomonaga M, Kamada N, et al. 1995. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906–916.

    PubMed  CAS  Google Scholar 

  35. Cannistra S, Tantravahi R, Robertson MJ, Griffin J, Canellos GP. 1990. Low-dose cytosine arabinoside induces cytogenetic remissions in patients with stable phase chronic myeloid leukemia (abstract). Blood 76 (Suppl 1):259a.

    Google Scholar 

  36. Kantarjian HM, Keating MJ, Estey EH, et al. 1992. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-a and low-dose cytarabine. J Clin Oncol 10:772–778.

    PubMed  CAS  Google Scholar 

  37. Guilhot F, Tanzer J, Bauters F, et al. 1991. A multicenter randomized study of alpha 2b interferon and hydroxyurea with or without cytosine-arabinoside in previously untreated patients with Ph+ CML. Leuk Lymphoma 11 (Suppl 1):181–183.

    Google Scholar 

  38. Lengyel P. 1982. Biochemistry of interferons and their actions. Annu Rev Biochem 51:251–282.

    PubMed  CAS  Google Scholar 

  39. Maxwell B, Talpaz M, Gutterman JU. 1985. Down-regulation of peripheral blood cell interferon receptors in chronic myelogeneous leukemia patients undergoing human interferon (HuIFN) therapy. Int J Cancer 36:23–28.

    PubMed  CAS  Google Scholar 

  40. Rosenblum M, Maxwell B, Talpaz M, et al. 1986. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to alpha interferon: correlation with receptor binding and induction of 2’5’ oligoadenylate synthetase. Cancer Res 46:4848–4852.

    PubMed  CAS  Google Scholar 

  41. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM. 1994. Interferon-a restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired 1:11 integrin receptor function. J Clin Invest 94:384–391.

    PubMed  CAS  Google Scholar 

  42. McMahon M, Stark GR, Kerr IM. 1986. Interferon-induced gene expression in wild-type and interferon-resistant human lymphoblastoid (Daudi) cells. J Virol 57:362–366.

    PubMed  CAS  Google Scholar 

  43. Dron M, Modjtahedi N, Brison O, et al. 1986. Interferon modulation of c-myc expression in cloned daudi cells: relationship to the phenotype of interferon resistance. Mol Cell Biol 6:1374–1378.

    PubMed  CAS  Google Scholar 

  44. Friedman RL, Stark GR. 1985. α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 314:637–639.

    PubMed  CAS  Google Scholar 

  45. Kurzrock R, Talpaz M, Kantarjian H, et al. 1987. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70:943–947.

    PubMed  CAS  Google Scholar 

  46. Wandl UB, Kloke O, Nagel-Hiemke M, et al. 1992. Combination therapy with interferon alpha-2b plus low-dose interferon-gamma in pretreated patients with Ph-positive chronic myelogeneous leukemia. Br J Haematol 81:516–519.

    PubMed  CAS  Google Scholar 

  47. Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. 1991. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. Cancer 68:2125–2130.

    PubMed  CAS  Google Scholar 

  48. Ratain MJ, Larson RA, Hooberman A, Pape L, Wallenberg J, Marcus S. 1988. Phase II study of recombinant beta interferon in chronic myelogenous leukemia (abstract). Blood 72 (Suppl I):797a.

    Google Scholar 

  49. Kessler CM, Klein HG, Havlik RI. 1982. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol 50:157–167.

    PubMed  CAS  Google Scholar 

  50. Hehlmann R, Jahn M, Baumann B, et al. 1988. Essential thrombocythemia: clinical characteristics and course of 61 patients. Cancer 61:2487–2496.

    PubMed  CAS  Google Scholar 

  51. Wu KK. 1978. Platelet hyperaggregability in patients with thrombocythemia. Ann Intern Med 88:7–11.

    PubMed  CAS  Google Scholar 

  52. Talpaz M, Mavligit G, Keating M, et al. 1983. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Am J Med 99:789–792.

    CAS  Google Scholar 

  53. Talpaz M, Kurzrock R, Kantarjian H, et al. 1989. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am J Med 86:554–558.

    PubMed  CAS  Google Scholar 

  54. Giles FJ, Gray AG, Brozovic M, et al. 1989. Alpha-interferon therapy for essential thrombocythaemia. Lancet 1:634–637.

    Google Scholar 

  55. Velu T, Delwiche F, Gangji D, et al. 1985. Therapeutic effect of human recombinant interferon-alpha-2c in essential thrombocythaemia. Oncology 42:10–14.

    PubMed  Google Scholar 

  56. Gisslinger H, Linkesch W, Fritz E, et al. 1989. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1:634–637.

    PubMed  CAS  Google Scholar 

  57. May D, Wandl UB, Niederle N. 1989. Treatment of essential thrombocythaemia with interferon alpha-2b. Lancet 1:96.

    PubMed  CAS  Google Scholar 

  58. Bellucci S, Harousseau JL, Brice P, et al. 1988. Treatment of essential thrombocythaemia by alpha2a interferon. Lancet 2:960–961.

    PubMed  CAS  Google Scholar 

  59. Kasparu H, Reisner R, Bernhart M, et al. 1987. Recombinant alpha-2b interferon in the treatment of essential thrombocythaemia. Blut 55:284–287.

    Google Scholar 

  60. Middlehoff G, Boll I. 1992. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol 64:207–209.

    Google Scholar 

  61. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. 1986. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 23:132–143.

    PubMed  CAS  Google Scholar 

  62. Donovan PB, Kaplan ME, Goldberg JD, et al. 1984. Treatment of polycythemia vera with hydroxyurea. Am J Hematol 17:329–334.

    PubMed  CAS  Google Scholar 

  63. Silver RT. 1993. Interferon-alpha-2b: A new treatment for polycythemia vera. Ann Intern Med 119:1091–1092.

    PubMed  CAS  Google Scholar 

  64. Jimenez SA, Freundlich B, Rosenbloom J. 1984. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 74:1112–1116.

    PubMed  CAS  Google Scholar 

  65. Wickramasinghe SN, Peart S, Gill DS. 1987. Alpha-interferon in primary idiopathic myelofibrosis. Lancet 2:1524–1525.

    PubMed  CAS  Google Scholar 

  66. Radin AI, Buckley P, Duffy TP. 1991. Interferon therapy for agnogenic myeloid metasplasia complicated by immune hemolytic anemia. Hematol Pathol 5:83–88.

    PubMed  CAS  Google Scholar 

  67. Bouroncle BA, Wiseman BK, Doan CA. 1958. Leukemic reticuloendotheliosis. Blood 13:609–611.

    PubMed  CAS  Google Scholar 

  68. Golomb HM, Catovsky D, Golde DW. 1978. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677–683.

    PubMed  CAS  Google Scholar 

  69. Golomb HM, Catovsky D, Golde DW. 1983. Hairy cell leukemia: a five-year update on seventy-one patients. Ann Intern Med 99:485–486.

    PubMed  CAS  Google Scholar 

  70. Golomb HM. 1983. Hairy cell leukemia: lessons learned in twenty-five years. J Clin Oncol 1:652–656.

    PubMed  CAS  Google Scholar 

  71. Catovsky D, Pettit JE, Galton DAG, Splers SD, Harrison CV. 1974. Leukaemic reticuloendotheliosis (`hairy’ cell leukaemia): a distinct clinicopathological entity. Br J Haematol 26:9–27.

    PubMed  CAS  Google Scholar 

  72. Fitzpatrick J, O’Donnell A, DiLoro A, Bhargava A. 1986. Serum M-proteins in hairy cell leukemia, chronic lymphocytic leukemia and free ligh chain myeloma causing high resolution electropheresis/immunofixation (abstract). Blood 69:208A.

    Google Scholar 

  73. Rosove MH, Naeim F, Harwig S, Zighelboim J. 1980. Severe platelet dysfunction in hairy cell leukemia with improvement after splenectomy. Blood 55:903–906.

    PubMed  CAS  Google Scholar 

  74. Cawley JC, Burns GF, Hayhoe RGH. 1980. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy cell leukemia. Leuk Res 4:547–559.

    PubMed  CAS  Google Scholar 

  75. Catovsky D, Pettit JE, Galetto J, Okos A, Galton DAG. 1974. The B-lymphocyte nature of the hairy cell of leukemic reticuloendotheliosis. Br J Haematol 26:29–37.

    PubMed  CAS  Google Scholar 

  76. Jansen J, LeBien TW, Kersey JH. 1982. The phenotype of the neoplastic cells of hairy cell leukemia studies with monoclonal antibodies. Blood 59:609–614.

    PubMed  CAS  Google Scholar 

  77. Worman CP, Brooks DA, Hogg N, Zola H, Beverley PCL, Cawley JD. 1983. The nature of hairy cells: a study with a panel of monoclonal antibodies. Scand J Haematol 30:223–226.

    PubMed  CAS  Google Scholar 

  78. Divine M, Farcet JP, Gourdin MF, et al. 1984. Phenotype study of fresh and cultured hairy cells with the use of immunologic markers and electron microscopy. Blood 64:547–552.

    PubMed  CAS  Google Scholar 

  79. Anderson KC, Park EK, Bates MP, et al. 1983. Antigens on human plasma cells identified by monoclonal antibodies. J Immunol 130:1132–1138.

    PubMed  CAS  Google Scholar 

  80. Anderson KA, Boyd AW, Fisher DC, et al. 1985. Hairy cell leukemia: a tumor of pre-plasma cells. Blood 65:620–629.

    PubMed  CAS  Google Scholar 

  81. Cleary ML, Woods GS, Warnke R, Chao J, Sklar J. 1984. Immunoglobulin gene rearrangements in hairy cell leukemia. Blood 64:99–104.

    PubMed  CAS  Google Scholar 

  82. Korsmeyer SJ, Greene WC, Cossman J, et al. 1983. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci USA 80:4522–4526.

    PubMed  CAS  Google Scholar 

  83. Visser L, Shaw A, Slupsky J, Vos H, Poppema S. 1989. Monoclonal antibodies reactive with hairy cell leukemia. Blood 74:320–325.

    PubMed  CAS  Google Scholar 

  84. Li CY, Yam LT, Lam KW. 1970. Studies of acid phosphatase isoenzymes in human leukocytes: demonstration of isoenzyme cell specificity. J Histochem Cytochem 18:901–910.

    PubMed  CAS  Google Scholar 

  85. Quesada JR, Reuben J, Manning JT, et al. 1984. Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310:15–18.

    PubMed  CAS  Google Scholar 

  86. Worman CP, Catovsky D, Cawley JC, et al. 1987. The U.K. experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases. Leukemia 1:320–322.

    PubMed  CAS  Google Scholar 

  87. Kamasio EE, Bernasconi C, Castoldi GL, et al. 1987. Human lymphoblastoid interferon for hairy cell leukemia: results from the Italian cooperative group. Leukemia 1:331–333.

    Google Scholar 

  88. Foon KA, Maluish AE, Abrams PG, et al. 1986. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: therapeutic and immunologic results. Am J Med 80:351–356.

    PubMed  CAS  Google Scholar 

  89. Golomb HM, Jacobs A, Fefer A, et al. 1986. Alpha-2 interferon therapy of hairy cell leukemia: a multicenter study of 64 patients. J Clin Oncol 4:900–905.

    PubMed  CAS  Google Scholar 

  90. Dadmarz R, Evans T, Secher D, et al. 1987. Hairy cells possess more interferon receptors than other lymphoid cell types. Leukemia 1:357–361.

    PubMed  CAS  Google Scholar 

  91. Schwarzmeier JD, Schwabe M, Wagner L, et al. 1987. Effect of alpha-2-interferon on hairy cells and cell lines: a role for type I interferon receptors and RNA synthesis. Leukemia 1:361–365.

    PubMed  CAS  Google Scholar 

  92. Faltynek CR, Princier GL, Rossio JL, et al. 1986. Relationship of the clinical response and binding of recombinant interferon alpha in patients with lymphoproliferative diseases. Blood 67:1077–1082.

    PubMed  CAS  Google Scholar 

  93. Billard C, Sigaux F, Castaigne S, et al. 1986. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells. Blood 67:821–826.

    PubMed  CAS  Google Scholar 

  94. Billard C, Ferbus D, Sigaux F, et al. 1988. Action of interferon-alpha on hairy cell leukemia: expression of specific receptors and (2’-5’) oligo (A) synthetase in tumor cells from sensitive and resistant patients. Leukemia Res 12:11–18.

    CAS  Google Scholar 

  95. Nielsen B, Hokland M, Justesen J, et al. 1989. Immunological recovery and dose evaluation in IFN-alpha treatment of hairy cell leukemia: analysis of leukocyte differentiation antigens, NK and 2’,5’-oligoadenylate synthetase activity. Eur J Haematol 42:50–59.

    PubMed  CAS  Google Scholar 

  96. Samuels BL, Golomb HM, Brownstein BH. 1986. In vitro induction of proteins by alpha-interferon in hairy cell leukemia. Cancer Res 46:4151–4155.

    PubMed  CAS  Google Scholar 

  97. Samuels BL, Golomb HM, Brownstein BH. 1987. In vivo induction of proteins during therapy of hairy cell leukemia with alpha-interferon. Blood 69:1570–1573.

    PubMed  CAS  Google Scholar 

  98. Paganelli KA, Evans SS, Han T, et al. 1986. B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 67:937–942.

    PubMed  CAS  Google Scholar 

  99. Mongini P, Seremetis S, Blessinger C, et al. 1988. Diversity in inhibitory effects of IFNgamma and IFN-alpha A on the induced DNA synthesis of a hairy cell leukemia B lymphocyte clone reflects the nature of the activating ligand. Blood 72:1553–1559.

    PubMed  CAS  Google Scholar 

  100. Ruco LP, Procopio A, Maccallini V, et al. 1983. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 61:1132–1137.

    PubMed  CAS  Google Scholar 

  101. Griffiths SD, Cawley JC. 1987. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytoxicity. Leukemia 1:372–376.

    PubMed  CAS  Google Scholar 

  102. Starling GC, Nimmo JC, Hart DNJ. 1988. Hairy cell leukemia cells are relatively NKresistant targets. Pathology 20:361–365.

    PubMed  CAS  Google Scholar 

  103. Baldini L, Cortelezzi A, Polli N, et al. 1986. Human recombinant interferon alpha-2c enhances the expression of class II HLC antigens on hairy cells. Blood 67:458–464.

    PubMed  CAS  Google Scholar 

  104. Naeim F, Jacobs AD. 1985. Bone marrow changes in patients with hairy cell leukemia treated by recombinant alpha-2-interferon. Human Pathol 16:1200–1205.

    CAS  Google Scholar 

  105. Bardawil RG, Ratain MJ, Golomb HM, et al. 1987. Changes in peripheral blood and bone marrow specimens during and after alpha-2b-interferon therapy for hairy cell leukemia. Leukemia 1:340–343.

    PubMed  CAS  Google Scholar 

  106. Flandrin G, Sigaux F, Castaigne S, et al. 1986. Treatment of hairy cell leukemia with recombinant alpha interferon: I Quantitative study of bone marrow changes during the first months of treatment. Blood 67:817–820.

    PubMed  CAS  Google Scholar 

  107. Steis RG, Smith JW II, Urba JW, et al. 1988. Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409–1413.

    PubMed  CAS  Google Scholar 

  108. Spiers SDC, Moore D, Cassileth PA, et al. 1987. Hairy cell leukemia: complete remission with pentostatin (2’deoxycoformycin). N Engl J Med 316:825–830.

    PubMed  CAS  Google Scholar 

  109. Saven A, Piro LD. 1992. Treatment of hairy cell leukemia. Blood 79:1111–1120.

    PubMed  CAS  Google Scholar 

  110. Urba WJ, Baselor MW, Kopp WC, et al. 1989. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73:38–46.

    PubMed  CAS  Google Scholar 

  111. Foon KA, Nakano GM, Koller CA, Longo DL, Steis RG. 1986. Response to 2’deoxycoformycin after failure of interferon-a in nonsplenectomized patients with hairy cell leukemia. Blood 68:297–300.

    PubMed  CAS  Google Scholar 

  112. Piro LD, Carrera CJ, Carson DA, Butler E. 1990. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121.

    PubMed  CAS  Google Scholar 

  113. Cozzolino F, Torcia M, Adinucci D, et al. 1989. Production of interleukin-1 by bone marrow myeloma cells. Blood 74:380–387.

    PubMed  CAS  Google Scholar 

  114. Garrett IR, Durie BGM, Nedwin GE, et al. 1989. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317:526–530.

    Google Scholar 

  115. Bataille R, Klein B. 1991. The bone resorbing activity of interleukin-6. J Bone Miner Res 9:1143–1146.

    Google Scholar 

  116. Jacobson DR, Zolla-Pazner S. 1986. Immunosuppression and infection in multiple myeloma. Semin Oncol 2:282–290.

    Google Scholar 

  117. Broder S, Humphrey R, Durm M, et al. 1975. Impaired synthesis of (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. N Engl J Med 293:887–892.

    PubMed  CAS  Google Scholar 

  118. Solomon A, Weiss DT, Kattine AA. 1991. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 324:1845–1851.

    PubMed  CAS  Google Scholar 

  119. Alexanian R, Barlogie B, Dixon D. 1990. Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 150:1693–1695.

    PubMed  CAS  Google Scholar 

  120. Kyle RA, Greipp PR. 1983. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clinic Proc 58:665–683.

    CAS  Google Scholar 

  121. Spiers ASD, Halpern R, Ross SC, et al. 1980. Meningeal myelomatosis. Arch Intern Med 140:256–259.

    PubMed  CAS  Google Scholar 

  122. Pruzanski W, Watt JG. 1972. Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Ann Intern Med 77:853–860.

    PubMed  CAS  Google Scholar 

  123. Chandy KG, Stockley RG, Leonard RCF, et al. 1981. Relationships between serum viscosity and intravascular IgA polymer concentration in IgA myeloma. Clin Exp Immunol 46:653–661.

    PubMed  CAS  Google Scholar 

  124. Perkins HA, MacKenzie MR, Fudenberg HH. 1970. Haemostatic defects in dysproteinaemias. Blood 35:695–707.

    PubMed  CAS  Google Scholar 

  125. Lackner H. 1973. Haemostatic abnormalities associated with dysproteinaemias. Serum Haematol 10:125–133.

    CAS  Google Scholar 

  126. Bergsagel DE, Sprague CC, Austin C, Griffith KM. 1962. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma IV: L-Phenylalanine mustard. Cancer Chemother Res 21:87–93.

    CAS  Google Scholar 

  127. Alexanian R, Haut A, Khan AU, et al. 1969. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 208:1680–1685.

    PubMed  CAS  Google Scholar 

  128. Boccadoro M, Marmont F, Tribalto M, et al. 1991. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9:444–448.

    PubMed  CAS  Google Scholar 

  129. Gregory WM, Richards MA, Malpas JS. 1992. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10:334–342.

    PubMed  CAS  Google Scholar 

  130. Salmon SE, Shadduck RK, Schilling A. 1967. Intermittent high dose prednisone therapy for multiple myeloma. Cancer Chemother Rep 51:179–187.

    PubMed  CAS  Google Scholar 

  131. Cooper MR, Dear K, McIntyre OR, et al. 1993. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a cancer and leukemia group B study. J Clin Oncol 11:155–160.

    Google Scholar 

  132. Österborg A, Björkholm M, Björeman M, et al. 1993. Natural interferon-a in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the myeloma group of central Sweden. Blood 81:1428–1434.

    PubMed  Google Scholar 

  133. Hjorth M, Westin J, Dahl IMS, et al. 1996. Interferon-a2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 124:212–222.

    CAS  Google Scholar 

  134. Browman GP, Bergsagel D, Sicheri D, et al. 1995. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13:2354–2360.

    PubMed  CAS  Google Scholar 

  135. Westin J, Rödjer S, Turesson I, et al. 1995. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 89:561–568.

    PubMed  CAS  Google Scholar 

  136. Foon KA, Sherwin SA, Abrams PG, et al. 1984. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leucocyte A interferon. N Engl J Med 311:1148–1152.

    PubMed  CAS  Google Scholar 

  137. McLaughlin P. 1993. The role of interferon in the therapy of low grade lymphoma. Leuk Lymphoma 10:17–20.

    PubMed  Google Scholar 

  138. Ozer H, Anderson JR, Peterson BA, et al. 1994. Combination trial of subcutaneous recombinant a213 interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin’s lymphoma. Med Pediatr Oncol 22:228–235.

    PubMed  CAS  Google Scholar 

  139. Anderson JW, Smalley RV. 1993. Interferon alfa plus chemotherapy for non-Hodgkin’s lymphoma: five-year follow-up. N Engl J Med 329:1821–1822.

    Google Scholar 

  140. McLaughlin P, Cabanillas F, Hagemeister FB, et al. 1993. CHOP-bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4:205–211.

    PubMed  CAS  Google Scholar 

  141. Hagenbeek A, Carde P, Somers R, et al. 1992. Maintenance of remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low-grade malignant non-Hodgkin’s lymphoma: results from a prospective, randomized phase III clinical trial in 331 patients. Blood 80:288A.

    Google Scholar 

  142. Bunn PA, Foon KA, Inde DC, et al. 1984. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101:484–487.

    PubMed  Google Scholar 

  143. Bunn PA Jr, Hoffman SJ, Norris D, et al. 1994. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121:592–602.

    PubMed  Google Scholar 

  144. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. 1993. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51:63–72.

    PubMed  CAS  Google Scholar 

  145. Gill PS, Ilarkington W, Kaplan MH, et al. 1995. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744–1748.

    PubMed  CAS  Google Scholar 

  146. Lauer SJ, Ochs J, Pollock BH, Buchanan GR. 1994. Recombinant alpha-2B interferon treatment for childhood T-lymphoblastic disease in relapse. Cancer 74:197–202.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Kenneth A. Foon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA

    Kenneth A. Foon M.D.

  2. College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA

    Hyman B. Muss M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Foon, K.A. (1998). Interferon therapy of hematologic malignancies. In: Foon, K.A., Muss, H.B. (eds) Biological and Hormonal Therapies of Cancer. Cancer Treatment and Research, vol 94. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6189-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6189-7_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7837-2

  • Online ISBN: 978-1-4615-6189-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation